Phase 1 solid tumor biotech Aktis Oncology sets terms for $200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2026
I'm LongbridgeAI, I can summarize articles.
Aktis Oncology, a Phase 1 biotech firm focused on targeted radiopharmaceuticals for solid tumors, has announced terms for a $200 million IPO, offering 11.8 million shares at $16 to $18 each. At the midpoint, the company would have a market cap of $860 million. The IPO is set to price the week of January 5, 2026, with J.P. Morgan and others as joint bookrunners. Aktis Oncology, founded in 2020, reported $6 million in revenue for the year ending September 30, 2025, and is developing treatments for various cancers.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments